slide 1

Back to the List of the Granted Patents                                                Click here to download AP2368 PDF

(11)    Patent No :    AP 2368    (73) Applicant(s)       
(21)    Application No :    AP/P/2003/002914    FIT BIOTECH OYJ PLC, Lenkkeilijankatu 10, FIN-33520       
            Tampere,       
                   
(22)    Filing Date :    03.05.2002    Finland       
(24)    Date of Grant &    27.02.2012           
                   
(45)    Publication :

(30)    Priority Data            (72) Inventors   
    (33) Country    (31) Number    (32) Date    KROHN Kai, Finland   
    FI    20010922    03.05.2001    BLAZEVIC Vesna, Finland   
    US    10/138,098    03.05.2002       
                TAHTINEN Maria, Finland   
                   
                et al       
                (74) Representative   
(84)    Designated State           
                   
    BW  GM  GH    KE   LS   MW    MZ   SL   SD    HONEY & BLANCKENBERG   
    SZ   T Z   UG   ZM   ZW               
(51)    International    Classification    A61P 31/12 (2006.01)    A61K 31/34 (2006.01)   
            A61P 31/18 (2006.01)   
(54)    Title

Novel expression vectors and uses thereof.

(57)    Abstract

The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The nuclear-anchoring protein might be the E2 protein of Bovine Papilloma Virus type 1 or Epslein -Barr Virus Nuclear Antigen 1. The invention also relates to vectors that lack an origin of replication functional in a mammalian cell. The invention further relates to methods fur expressing a DNA sequence of interest in a subject.

(56)    Documents Cited :    WO 9807876 A2    PNAS, Volume 13, Siu Chung Hung et al:    Gene Therapy, Volume 4,

1997,

S Mucke et al:    Vaccine, Volume 18, 2000, Auni Collings et al:    Virology, Volume 270,

2000,

Newsletter

Join our newsletter for CIPIT news through subscriptions!

SEND

Social Media

    

Contact Us

TEL : (254) 703 034 612